FDA 483 OBSERVATION · #186 OF 1,945 MOST-CITED

Written program not followed

FDA cited this observation 165 times across 151 firms in recent inspections. Below: how it breaks down by program area and fiscal year, and real examples of how FDA worded it on Form FDA 483.

BY PROGRAM AREA
Drugs165
BY FISCAL YEAR
FY202613
FY202519
FY202414
FY202313
FY202217
FY202112
FY20209
FY201919
FY201822
FY201714
FY201613

What this observation is associated with

Firms cited for this observation also appear in FDA compliance actions — warning letters, injunctions, or seizures — at 5× the rate of the average FDA-cited firm (39.1% vs 7.8%), across 151 FEI-matched firms.

This is an association, not causation, and reflects co-occurrence in FDA's records — not a claim that the observation caused or preceded the action.

CHECKING ACCESS

Checking your access…

How FDA worded it — real examples

The written stability testing program is not followed.

S.s.s. Company (international) · Atlanta, Georgia · Drugs · 2026-06-26

The written stability testing program is not followed.

Nowcos Co., Ltd. · Sejong · Drugs · 2026-06-19

The written stability testing program is not followed.

The Procter & Gamble Manufacturing Company · Greensboro, North Carolina · Drugs · 2026-06-09

The written stability testing program is not followed.

PPL Healthcare LLC · Sellersville, Pennsylvania · Drugs · 2026-05-08

The written stability testing program is not followed.

Best Sanitizers Inc · Walton, Kentucky · Drugs · 2026-05-01

The written stability testing program is not followed.

Granules Pharmaceuticals Inc. · Chantilly, Virginia · Drugs · 2026-04-03

Related SPEQ references

Where to read the requirements behind this observation area on SPEQ. These are SPEQ's topic and audience pages — not an FDA classification of the citation.

Pharma industry →

Examples are a representative sample of FDA's published inspection observations. Open the 483 observation explorer →